PTPN11 gain-of-function mutations (e.g., Noonan syndrome) ablate the autoinhibited binding of the N-SH2 (N-terminal SH2) domain on the PTP, actively creating a situation where SHP2 is constitutively activated with complete freedom from having to rely on upstream signals. This evidence concerns the gene PTPN11 and Noonan syndrome.